US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Skye Bioscience Inc.

0.2800

-0.0004-0.14%

Post-market: 0.2763-0.0037-1.30%19:49 EDT

Volume:974.58K

Turnover:263.16K

Market Cap:9.84M

PE:-0.22

High:0.2840

Open:0.2804

Low:0.2550

Close:0.2804

52wk High:4.99

52wk Low:0.2550

Shares:35.13M

Float Shares:22.95M

Volume Ratio:0.23

T/O Rate:4.25%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.2800

EPS(LYR):-1.4100

ROE:-233.87%

ROA:-96.22%

PB:-19.78

PE(LYR):-0.20

Loading ...

Overview Company News Filings

Skye Bioscience Lawsuit: MFDI Seeks Dismissal of Securities Claims Against It

Skye Bioscience Lawsuit: Company and CEO Move to Dismiss Claims

Cadrenal Therapeutics Names John P. Sharp Interim CFO, Replacing Quang X. Pham

SkyeChip Signs Deal for ARM Flexible Access Token Under MIDA Program

MT Newswires Live

Skye Bioscience transfers Nasdaq listing to Capital Market tier effective June 23

Skye Bioscience raises authorized common shares to 300,000,000 from 100,000,000

Skye Bioscience opens higher-dose Cohort 2 in nimacimab obesity Phase 2a study

UOB Kay Hian Starts SkyeChip at Buy with MYR2.08 Price Target

MT Newswires Live

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data From First Four Participants Treated in Cohort 1

THOMSON REUTERS

Skye Bioscience Inc - Crc Approves Enrollment in Cohort 2 (600 Mg Iv) After Favorable Safety Review of Cohort 1

THOMSON REUTERS

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

Skye Bioscience receives Nasdaq notice for falling below $10 million equity minimum

Skye Bioscience posts corporate presentation on nimacimab obesity drug development strategy

Update – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

THOMSON REUTERS

U.S. RESEARCH ROUNDUP-Accuray, Aevex, Zoetis

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Coherus Biosciences (CHRS), Moderna (MRNA) and Skye Bioscience (SKYE)

Skye Bioscience Inc : Piper Sandler Cuts Target Price to $6 From $13

THOMSON REUTERS

Skye Bioscience Q1 EPS $(0.32) Misses $(0.31) Estimate

Benzinga Earnings

Skye Bioscience Q1 FY26 net loss widens to $12.51 million; operating loss rises to $12.67 million

Skye Bioscience Inc expected to post a loss of 31 cents a share - Earnings Preview

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/SKYE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SKYE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SKYE\",,,,,undefined,":{"symbol":"SKYE","market":"US","secType":"STK","nameCN":"Skye Bioscience Inc.","latestPrice":0.28,"timestamp":1787342400000,"preClose":0.2804,"halted":3,"volume":974577,"hourTrading":{"tag":"盘后","latestPrice":0.276347,"preClose":0.28,"latestTime":"19:49 EDT","volume":14195,"amount":3930.894364,"timestamp":1787356181146,"change":-0.003653,"changeRate":-0.013046,"amplitude":0.030714},"delay":0,"changeRate":-0.0014265335235376462,"floatShares":22951600,"shares":35126884,"eps":-1.279983,"marketStatus":"Halted","change":-0.0004,"latestTime":"08-21 16:00:00 EDT","open":0.2804,"high":0.284,"low":0.255,"amount":263161.76247704995,"amplitude":0.103424,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.279983,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"symbolChange":{"newSymbol":"SKYED","executeDate":"2023-09-08"},"adr":0,"exchange":"NASDAQ","adjPreClose":0.2804,"preHourTrading":{"tag":"盘前","latestPrice":0.284,"preClose":0.2804,"latestTime":"09:25 EDT","volume":15172,"amount":4305.8811153999995,"timestamp":1787318730587,"change":0.0036,"changeRate":0.012839,"amplitude":0.044579},"postHourTrading":{"tag":"盘后","latestPrice":0.276347,"preClose":0.28,"latestTime":"19:49 EDT","volume":14195,"amount":3930.894364,"timestamp":1787356181146,"change":-0.003653,"changeRate":-0.013046,"amplitude":0.030714},"volumeRatio":0.23365413386026426,"impliedVol":0.9132,"impliedVolPercentile":0.2231},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SKYE\",,,,,undefined,":{"symbol":"SKYE","floatShares":22951600,"roa":"-96.22%","roe":"-233.87%","lyrEps":-1.410011,"volumeRatio":0.23365413386026426,"shares":35126884,"dividePrice":0,"high":0.284,"amplitude":0.103424,"preClose":0.2804,"low":0.255,"week52Low":0.255,"pbRate":"-19.78","week52High":4.9902,"institutionHeld":0,"latestPrice":0.28,"eps":-1.279983,"divideRate":0,"volume":974577,"delay":0,"ttmEps":-1.279983,"open":0.2804,"prevYearClose":0.7497,"prevWeekClose":0.5015,"prevMonthClose":0.5685,"prevQuarterClose":0.6933,"fiveDayClose":0.5015,"twentyDayClose":0.6519,"sixtyDayClose":0.8285},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SKYE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-24","symbol":"SKYE","defaultRemindTime":1787578200000,"type":"split","dateTimestamp":1787544000000,"forFactor":8,"toFactor":1,"ratio":8},{"market":"US","date":"2026-08-14","symbol":"SKYE","fiscalQuarterEnding":"2026/06","expectedEps":-0.29,"name":null,"time":"","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"","actualEps":-0.27},{"market":"US","date":"2026-05-11","symbol":"SKYE","fiscalQuarterEnding":"2026/03","expectedEps":-0.29,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-0.32},{"market":"US","date":"2026-03-10","symbol":"SKYE","fiscalQuarterEnding":"2025/12","expectedEps":-0.29,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1773115200000,"reportTimeType":"post","actualEps":-0.36},{"market":"US","date":"2025-11-10","symbol":"SKYE","fiscalQuarterEnding":"2025/09","expectedEps":-0.33,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"post","actualEps":-0.32}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SKYE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SKYE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.6667,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1759809600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SKYE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SKYE","date":"2026-08-21","current":-0.218753,"percent":1,"low":-12.94129,"twenty":-4.274381,"median":-2.530385,"eighty":-0.500548,"high":-0.195163,"avg":-2.911256,"sd":2.607059,"marketCap":9854299},"quantilePoints":[{"date":"2024-04-12","current":-9.459964,"twenty":-9.513638,"median":-9.459964,"eighty":-7.885539,"marketCap":356118289},{"date":"2024-04-19","current":-12.650558,"twenty":-12.435864,"median":-9.657512,"eighty":-9.495746,"marketCap":476227531},{"date":"2024-04-26","current":-9.579238,"twenty":-12.081022,"median":-9.691058,"eighty":-9.561347,"marketCap":360608354},{"date":"2024-05-03","current":-9.683603,"twenty":-11.635233,"median":-9.68733,"eighty":-9.561347,"marketCap":364537161},{"date":"2024-05-10","current":-8.997775,"twenty":-10.807766,"median":-9.638876,"eighty":-9.507673,"marketCap":338719287},{"date":"2024-05-17","current":-9.168,"twenty":-10.15772,"median":-9.601602,"eighty":-9.22813,"marketCap":343770610},{"date":"2024-05-24","current":-8.952556,"twenty":-9.700003,"median":-9.54942,"eighty":-8.9931,"marketCap":335692167},{"date":"2024-05-31","current":-8.720508,"twenty":-9.691058,"median":-9.489815,"eighty":-8.983995,"marketCap":326991116},{"date":"2024-06-07","current":-8.47349,"twenty":-9.691058,"median":-9.389145,"eighty":-8.952556,"marketCap":317728707},{"date":"2024-06-14","current":-8.069277,"twenty":-9.691058,"median":-9.18753,"eighty":-8.690567,"marketCap":302572037},{"date":"2024-06-21","current":-6.684476,"twenty":-9.685094,"median":-9.060284,"eighty":-8.473188,"marketCap":250646409},{"date":"2024-06-28","current":-5.434411,"twenty":-9.674658,"median":-9.022864,"eighty":-8.245631,"marketCap":203773004},{"date":"2024-07-05","current":-5.58412,"twenty":-9.638876,"median":-8.993879,"eighty":-7.844715,"marketCap":209386586},{"date":"2024-07-12","current":-4.873005,"twenty":-9.631421,"median":-8.980898,"eighty":-7.11863,"marketCap":182722074},{"date":"2024-07-15","current":-4.820607,"twenty":-9.62993,"median":-8.974213,"eighty":-6.892464,"marketCap":180757321},{"date":"2024-08-02","current":-4.102007,"twenty":-9.628439,"median":-8.967527,"eighty":-6.745055,"marketCap":153812130},{"date":"2024-08-09","current":-3.735222,"twenty":-9.606075,"median":-8.870216,"eighty":-5.58412,"marketCap":140058855},{"date":"2024-08-16","current":-3.615791,"twenty":-9.579238,"median":-8.690567,"eighty":-4.690361,"marketCap":152904981},{"date":"2024-08-23","current":-3.787972,"twenty":-9.567311,"median":-8.506414,"eighty":-4.17237,"marketCap":160186171},{"date":"2024-08-30","current":-4.584307,"twenty":-9.543456,"median":-8.189044,"eighty":-4.185844,"marketCap":193861673},{"date":"2024-09-06","current":-4.347559,"twenty":-9.525571,"median":-8.069277,"eighty":-4.204574,"marketCap":183850037},{"date":"2024-09-13","current":-4.304513,"twenty":-9.489808,"median":-7.545298,"eighty":-4.204574,"marketCap":182029740},{"date":"2024-09-20","current":-3.93863,"twenty":-9.483818,"median":-7.11863,"eighty":-4.170873,"marketCap":166557212},{"date":"2024-09-27","current":-2.840979,"twenty":-9.431636,"median":-6.35886,"eighty":-4.072065,"marketCap":120139628},{"date":"2024-10-04","current":-2.56836,"twenty":-9.296072,"median":-5.58412,"eighty":-3.802872,"marketCap":108611078},{"date":"2024-10-11","current":-2.683147,"twenty":-9.199248,"median":-5.224584,"eighty":-3.740033,"marketCap":113465204},{"date":"2024-10-18","current":-3.034682,"twenty":-9.153032,"median":-4.873005,"eighty":-3.308736,"marketCap":128330966},{"date":"2024-10-25","current":-3.501004,"twenty":-9.080009,"median":-4.593919,"eighty":-3.325954,"marketCap":148050855},{"date":"2024-10-31","current":-3.651662,"twenty":-9.02741,"median":-4.557114,"eighty":-3.343172,"marketCap":154421896},{"date":"2024-11-08","current":-7.770049,"twenty":-9.018318,"median":-4.55561,"eighty":-3.379043,"marketCap":165040297},{"date":"2024-11-15","current":-7.870031,"twenty":-8.997775,"median":-4.571462,"eighty":-3.501004,"marketCap":167163977},{"date":"2024-11-22","current":-5.956085,"twenty":-8.989983,"median":-4.820607,"eighty":-3.501004,"marketCap":126510669},{"date":"2024-11-29","current":-6.413147,"twenty":-8.983995,"median":-4.921494,"eighty":-3.53544,"marketCap":136218922},{"date":"2024-12-06","current":-5.070528,"twenty":-8.981218,"median":-5.25247,"eighty":-3.595703,"marketCap":107700929},{"date":"2024-12-13","current":-4.784865,"twenty":-8.970201,"median":-5.21336,"eighty":-3.614356,"marketCap":101633271},{"date":"2024-12-20","current":-4.084989,"twenty":-8.95555,"median":-5.042643,"eighty":-3.644488,"marketCap":86767509},{"date":"2024-12-27","current":-3.799325,"twenty":-8.952556,"median":-4.89725,"eighty":-3.64221,"marketCap":80699851},{"date":"2025-01-03","current":-4.070706,"twenty":-8.886684,"median":-4.82416,"eighty":-3.64221,"marketCap":86464126},{"date":"2025-01-10","current":-4.427785,"twenty":-8.774403,"median":-4.734873,"eighty":-3.64221,"marketCap":94048699},{"date":"2025-01-17","current":-3.856458,"twenty":-8.71452,"median":-4.60353,"eighty":-3.6441,"marketCap":81913383},{"date":"2025-01-24","current":-3.727909,"twenty":-8.690567,"median":-4.558618,"eighty":-3.651662,"marketCap":79182936},{"date":"2025-01-31","current":-5.356192,"twenty":-8.660625,"median":-4.557114,"eighty":-3.694707,"marketCap":113768587},{"date":"2025-02-07","current":-4.256387,"twenty":-8.539337,"median":-4.55561,"eighty":-3.699343,"marketCap":90408104},{"date":"2025-02-14","current":-4.370652,"twenty":-8.47349,"median":-4.466458,"eighty":-3.699343,"marketCap":92835167},{"date":"2025-02-21","current":-4.470635,"twenty":-8.472282,"median":-4.477777,"eighty":-3.722196,"marketCap":94958847},{"date":"2025-02-28","current":-3.827892,"twenty":-8.245631,"median":-4.442068,"eighty":-3.730044,"marketCap":81306617},{"date":"2025-03-07","current":-3.670777,"twenty":-8.162365,"median":-4.40636,"eighty":-3.699343,"marketCap":77969405},{"date":"2025-03-14","current":-3.463671,"twenty":-8.134468,"median":-4.354733,"eighty":-3.698416,"marketCap":73570353},{"date":"2025-03-21","current":-2.203547,"twenty":-8.081254,"median":-4.304513,"eighty":-3.649772,"marketCap":58541914},{"date":"2025-03-28","current":-2.471704,"twenty":-7.90988,"median":-4.297339,"eighty":-3.6255,"marketCap":65666062},{"date":"2025-04-04","current":-1.632257,"twenty":-7.858605,"median":-4.256387,"eighty":-3.582221,"marketCap":43364381},{"date":"2025-04-11","current":-1.562303,"twenty":-7.846922,"median":-4.225597,"eighty":-3.501004,"marketCap":41505907},{"date":"2025-04-17","current":-1.842119,"twenty":-7.799915,"median":-4.189726,"eighty":-3.364695,"marketCap":48939801},{"date":"2025-04-25","current":-2.086958,"twenty":-7.727199,"median":-4.165203,"eighty":-3.259602,"marketCap":55444458},{"date":"2025-05-02","current":-2.366773,"twenty":-7.630073,"median":-4.156405,"eighty":-3.056205,"marketCap":62878352},{"date":"2025-05-09","current":-1.698098,"twenty":-7.560926,"median":-4.127838,"eighty":-2.911286,"marketCap":55444458},{"date":"2025-05-16","current":-1.907406,"twenty":-7.545298,"median":-4.116978,"eighty":-2.799369,"marketCap":62278559},{"date":"2025-05-23","current":-1.964344,"twenty":-7.500386,"median":-4.077848,"eighty":-2.746856,"marketCap":64137621},{"date":"2025-05-30","current":-2.011792,"twenty":-7.329718,"median":-4.070706,"eighty":-2.683147,"marketCap":65686838},{"date":"2025-06-06","current":-2.040261,"twenty":-7.099247,"median":-4.06458,"eighty":-2.616276,"marketCap":66616369},{"date":"2025-06-13","current":-2.05924,"twenty":-6.976473,"median":-4.013573,"eighty":-2.54373,"marketCap":67236056},{"date":"2025-06-20","current":-2.030771,"twenty":-6.805634,"median":-3.979786,"eighty":-2.387759,"marketCap":66306526},{"date":"2025-06-27","current":-4.033073,"twenty":-6.650207,"median":-3.970723,"eighty":-2.387759,"marketCap":131683521},{"date":"2025-07-03","current":-4.374698,"twenty":-6.513129,"median":-3.970723,"eighty":-2.471704,"marketCap":142837890},{"date":"2025-07-11","current":-3.738896,"twenty":-6.413147,"median":-3.970723,"eighty":-2.503792,"marketCap":122078370},{"date":"2025-07-18","current":-3.530125,"twenty":-6.413147,"median":-3.966646,"eighty":-2.541658,"marketCap":115261811},{"date":"2025-07-25","current":-3.805323,"twenty":-6.298881,"median":-3.947535,"eighty":-2.546837,"marketCap":124247275},{"date":"2025-08-01","current":-3.387782,"twenty":-6.198899,"median":-3.902759,"eighty":-2.561185,"marketCap":110614158},{"date":"2025-08-08","current":-3.368802,"twenty":-6.1132,"median":-3.885025,"eighty":-2.56836,"marketCap":109994470},{"date":"2025-08-15","current":-2.391434,"twenty":-6.1132,"median":-3.856458,"eighty":-2.546837,"marketCap":101332133},{"date":"2025-08-22","current":-2.596205,"twenty":-6.1132,"median":-3.856458,"eighty":-2.541658,"marketCap":110008891},{"date":"2025-08-29","current":-2.545012,"twenty":-6.033244,"median":-3.838191,"eighty":-2.530385,"marketCap":107839701},{"date":"2025-09-05","current":-2.74247,"twenty":-6.003302,"median":-3.805323,"eighty":-2.498872,"marketCap":116206575},{"date":"2025-09-12","current":-3.115445,"twenty":-5.964031,"median":-3.793648,"eighty":-2.525066,"marketCap":132010669},{"date":"2025-09-19","current":-2.881421,"twenty":-5.898952,"median":-3.776855,"eighty":-2.539403,"marketCap":122094374},{"date":"2025-09-26","current":-2.632771,"twenty":-5.861816,"median":-3.757875,"eighty":-2.544341,"marketCap":111558312},{"date":"2025-10-03","current":-3.28365,"twenty":-5.684705,"median":-3.738896,"eighty":-2.546472,"marketCap":139138005},{"date":"2025-10-10","current":-1.257879,"twenty":-5.595667,"median":-3.729992,"eighty":-2.525066,"marketCap":53300082},{"date":"2025-10-17","current":-1.060422,"twenty":-5.58412,"median":-3.727909,"eighty":-2.468814,"marketCap":44933209},{"date":"2025-10-24","current":-1.060422,"twenty":-5.516043,"median":-3.699343,"eighty":-2.388509,"marketCap":44933209},{"date":"2025-10-31","current":-1.075048,"twenty":-5.447334,"median":-3.691448,"eighty":-2.317303,"marketCap":45552977},{"date":"2025-11-07","current":-1.111614,"twenty":-5.371836,"median":-3.676368,"eighty":-2.244599,"marketCap":47102398},{"date":"2025-11-14","current":-0.828708,"twenty":-5.321912,"median":-3.651662,"eighty":-2.178806,"marketCap":42454135},{"date":"2025-11-21","current":-0.782205,"twenty":-5.233356,"median":-3.64221,"eighty":-2.124921,"marketCap":40071826},{"date":"2025-11-28","current":-0.819751,"twenty":-5.18765,"median":-3.621859,"eighty":-2.093402,"marketCap":41995273},{"date":"2025-12-05","current":-0.757174,"twenty":-5.110521,"median":-3.608617,"eighty":-2.055444,"marketCap":38789527},{"date":"2025-12-12","current":-0.719628,"twenty":-5.037066,"median":-3.577936,"eighty":-2.025264,"marketCap":36866080},{"date":"2025-12-19","current":-0.625701,"twenty":-4.9588,"median":-3.549105,"eighty":-1.981949,"marketCap":32054255},{"date":"2025-12-26","current":-0.522137,"twenty":-4.912548,"median":-3.544049,"eighty":-1.945365,"marketCap":26748745},{"date":"2026-01-02","current":-0.469135,"twenty":-4.89913,"median":-3.530125,"eighty":-1.880836,"marketCap":24033478},{"date":"2026-01-09","current":-0.657052,"twenty":-4.893905,"median":-3.501657,"eighty":-1.841207,"marketCap":33660334},{"date":"2026-01-16","current":-0.60236,"twenty":-4.863947,"median":-3.501004,"eighty":-1.780246,"marketCap":30858511},{"date":"2026-01-23","current":-0.657052,"twenty":-4.827714,"median":-3.463671,"eighty":-1.698098,"marketCap":33660334},{"date":"2026-01-30","current":-0.600733,"twenty":-4.820607,"median":-3.430485,"eighty":-1.632257,"marketCap":30775162},{"date":"2026-02-06","current":-0.500298,"twenty":-4.784865,"median":-3.387782,"eighty":-1.562303,"marketCap":25629940},{"date":"2026-02-13","current":-0.451176,"twenty":-4.684882,"median":-3.355987,"eighty":-1.389518,"marketCap":23113429},{"date":"2026-02-20","current":-0.488221,"twenty":-4.650603,"median":-3.310888,"eighty":-1.249103,"marketCap":25011231},{"date":"2026-02-27","current":-0.482464,"twenty":-4.611231,"median":-3.270848,"eighty":-1.139404,"marketCap":24716302},{"date":"2026-03-06","current":-0.461814,"twenty":-4.588626,"median":-3.232166,"eighty":-1.117465,"marketCap":23658406},{"date":"2026-03-13","current":-0.421973,"twenty":-4.584426,"median":-3.115445,"eighty":-1.099913,"marketCap":23598786},{"date":"2026-03-20","current":-0.391057,"twenty":-4.563756,"median":-3.07414,"eighty":-1.060422,"marketCap":21869766},{"date":"2026-03-27","current":-0.368854,"twenty":-4.556212,"median":-3.020373,"eighty":-1.032631,"marketCap":20628076},{"date":"2026-04-02","current":-0.396846,"twenty":-4.55561,"median":-3.01306,"eighty":-0.904924,"marketCap":22193540},{"date":"2026-04-10","current":-0.433194,"twenty":-4.547475,"median":-2.991518,"eighty":-0.825125,"marketCap":24226306},{"date":"2026-04-17","current":-0.447638,"twenty":-4.524911,"median":-2.934243,"eighty":-0.813493,"marketCap":25034073},{"date":"2026-04-24","current":-0.564544,"twenty":-4.496344,"median":-2.903361,"eighty":-0.760929,"marketCap":31572043},{"date":"2026-05-01","current":-0.551982,"twenty":-4.476348,"median":-2.874108,"eighty":-0.754671,"marketCap":30869505},{"date":"2026-05-08","current":-0.56423,"twenty":-4.457052,"median":-2.850745,"eighty":-0.717125,"marketCap":31554479},{"date":"2026-05-15","current":-0.533788,"twenty":-4.44444,"median":-2.837542,"eighty":-0.67958,"marketCap":30602541},{"date":"2026-05-22","current":-0.4379,"twenty":-4.441321,"median":-2.797934,"eighty":-0.658929,"marketCap":25105183},{"date":"2026-05-29","current":-0.520738,"twenty":-4.435608,"median":-2.76565,"eighty":-0.638279,"marketCap":29854338},{"date":"2026-06-05","current":-0.474724,"twenty":-4.410645,"median":-2.74247,"eighty":-0.632021,"marketCap":27216309},{"date":"2026-06-12","current":-0.489857,"twenty":-4.380841,"median":-2.71105,"eighty":-0.613399,"marketCap":28083943},{"date":"2026-06-18","current":-0.435939,"twenty":-4.374698,"median":-2.686734,"eighty":-0.608898,"marketCap":24992777},{"date":"2026-06-26","current":-0.434248,"twenty":-4.373889,"median":-2.681566,"eighty":-0.585144,"marketCap":24895812},{"date":"2026-07-02","current":-0.413897,"twenty":-4.370652,"median":-2.632771,"eighty":-0.575703,"marketCap":23729041},{"date":"2026-07-10","current":-0.429651,"twenty":-4.354733,"median":-2.616316,"eighty":-0.564126,"marketCap":24632234},{"date":"2026-07-17","current":-0.385331,"twenty":-4.347559,"median":-2.596205,"eighty":-0.550977,"marketCap":22091343},{"date":"2026-07-24","current":-0.413774,"twenty":-4.304513,"median":-2.571313,"eighty":-0.54187,"marketCap":23722012},{"date":"2026-07-31","current":-0.355723,"twenty":-4.304513,"median":-2.566952,"eighty":-0.531458,"marketCap":20393901},{"date":"2026-08-07","current":-0.289151,"twenty":-4.300292,"median":-2.559638,"eighty":-0.518052,"marketCap":16577293},{"date":"2026-08-14","current":-0.331632,"twenty":-4.297719,"median":-2.545924,"eighty":-0.506842,"marketCap":19012753},{"date":"2026-08-21","current":-0.195163,"twenty":-4.274381,"median":-2.530385,"eighty":-0.500548,"marketCap":9854299}],"updateTime":1787540454318},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SKYE\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2655134298","title":"Skye Bioscience Lawsuit: MFDI Seeks Dismissal of Securities Claims Against It","url":"https://stock-news.laohu8.com/highlight/detail?id=2655134298","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655134298?lang=en_us&edition=fundamental","pubTime":"2026-07-30 03:05","pubTimestamp":1785351930,"startTime":"0","endTime":"0","summary":"Skye Bioscience (SKYE) is facing an investor securities lawsuit in the U.S. District Court for the Southern District of California, where sharehold...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/skye-bioscience-lawsuit-mfdi-seeks-dismissal-of-securities-claims-against-it?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/skye-bioscience-lawsuit-mfdi-seeks-dismissal-of-securities-claims-against-it?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SKYE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653778311","title":"Skye Bioscience Lawsuit: Company and CEO Move to Dismiss Claims","url":"https://stock-news.laohu8.com/highlight/detail?id=2653778311","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653778311?lang=en_us&edition=fundamental","pubTime":"2026-07-24 03:14","pubTimestamp":1784834087,"startTime":"0","endTime":"0","summary":"Skye Bioscience (SKYE) and its chief executive officer, Punit Dhillon, have asked a federal court in California to dismiss the claims against them ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/skye-bioscience-lawsuit-company-and-ceo-move-to-dismiss-claims?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/skye-bioscience-lawsuit-company-and-ceo-move-to-dismiss-claims?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SKYE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647307545","title":"Cadrenal Therapeutics Names John P. Sharp Interim CFO, Replacing Quang X. Pham","url":"https://stock-news.laohu8.com/highlight/detail?id=2647307545","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647307545?lang=en_us&edition=fundamental","pubTime":"2026-06-30 05:20","pubTimestamp":1782768007,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics names John P. Sharp interim CFO, replacing Quang X. PhamCadrenal Therapeutics named John P. Sharp interim CFO on June 25, replacing Quang X. Pham.Sharp is a senior director at Lo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL3zvXY0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","CVKD","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645864464","title":"SkyeChip Signs Deal for ARM Flexible Access Token Under MIDA Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2645864464","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645864464?lang=en_us&edition=fundamental","pubTime":"2026-06-24 13:46","pubTimestamp":1782279980,"startTime":"0","endTime":"0","summary":"SkyeChip  signed a definitive agreement with the Malaysian Investment Development Authority  for access to ARM's Flexible Access  token, according to a Tuesday Malaysian bourse filing.Shares slid over 1% in Wednesday's afternoon trade.The deal forms part of a strategic cooperation program between the Malaysian government and ARM.The agreement follows conditional approval letters issued by MIDA in April 2026 for access to both the ARM Compute Subsystem  and AFA tokens.SkyeChip added that it is still reviewing and evaluating the terms and conditions related to the separate CSS token agreement.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4543","LU2543165471.USD","LU0348723411.USD","ARMW","IE00BMPRXN33.USD","BK4609","ARM","ARMG","IE00BMPRXQ63.HKD","BK4141","BK4585","IE00BMPRXR70.SGD","LU0081259029.USD","ARMU","BK4139","BK4588","SKYE"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2645887482","title":"Skye Bioscience transfers Nasdaq listing to Capital Market tier effective June 23","url":"https://stock-news.laohu8.com/highlight/detail?id=2645887482","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645887482?lang=en_us&edition=fundamental","pubTime":"2026-06-23 18:02","pubTimestamp":1782208930,"startTime":"0","endTime":"0","summary":"Skye Bioscience will move its Nasdaq listing to the Nasdaq Capital Market effective June 23, 2026, keeping ticker SKYE.The shift follows a stockholders’ equity shortfall, with equity at $9.01 million versus the Nasdaq Global Market’s $10 million threshold.The Nasdaq Capital Market requires at least $3 million in stockholders’ equity.A separate minimum bid price deficiency remains in place, with a compliance deadline of Sept. 14, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 23, 2026, and is solely responsible","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDLcbsBRY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639677251","title":"Skye Bioscience raises authorized common shares to 300,000,000 from 100,000,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2639677251","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639677251?lang=en_us&edition=fundamental","pubTime":"2026-05-30 04:55","pubTimestamp":1780088129,"startTime":"0","endTime":"0","summary":"Skye Bioscience raised its authorized common stock to 300,000,000 shares from 100,000,000 in a Nevada charter amendment filed May 28, 2026.The change does not affect shares already issued or outstanding, expanding only the pool available for future issuance.Shareholders backed the increase at the May 26, 2026 annual meeting following a unanimous board recommendation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 29, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL9Vx17f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636084996","title":"Skye Bioscience opens higher-dose Cohort 2 in nimacimab obesity Phase 2a study","url":"https://stock-news.laohu8.com/highlight/detail?id=2636084996","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636084996?lang=en_us&edition=fundamental","pubTime":"2026-05-20 19:05","pubTimestamp":1779275100,"startTime":"0","endTime":"0","summary":"Skye Bioscience opened enrollment for Cohort 2 of its CBeyond Part C Expansion study, escalating weekly IV dosing of obesity drug candidate nimacimab to 600 mg following a safety review.The decision followed favorable early safety findings from the first four participants in Cohort 1 at 400 mg, with no neuropsychiatric adverse events reported to date.Results have not been presented; the study is designed to generate preliminary safety and pharmacokinetic readouts at higher exposures, with data expected in the future.The expansion compares nimacimab monotherapy with placebo over 15 weeks, positioning the program to support further development of a peripherally acting CB1 approach in obesity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL49Grzx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2095319765.USD","BK4588","IE00B64PRP62.GBP","SG9999014005.SGD","NDAQ","SG9999014021.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014039.USD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014013.SGD","BK4139","BK4112","SKYE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636613849","title":"UOB Kay Hian Starts SkyeChip at Buy with MYR2.08 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2636613849","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636613849?lang=en_us&edition=fundamental","pubTime":"2026-05-20 19:02","pubTimestamp":1779274979,"startTime":"0","endTime":"0","summary":"SkyeChip (KLSE:SKYECHIP) has an average rating of buy and mean price target of 1.60 ringgit, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0588545730.USD","LU0577902298.EUR","LU1988902786.USD","LU0264606111.USD","LU1242518857.USD","LU0210637038.USD","SG9999003826.SGD","LU1105468828.SGD","SG9999004220.SGD","LU0414403682.SGD","SGXZ58947870.SGD","SG9999014492.USD","LU0441851309.USD","SG9999005177.SGD","SG9999008742.SGD","LU0577902538.SGD","LU2506952097.USD","LU2449936058.SGD","LU1064131342.USD","LU0898667661.SGD","SGXZ27511609.SGD","LU0577902611.USD","SG9999001127.SGD","LU0315178854.USD","LU0737861269.HKD","SG9999006266.SGD","LU0950375773.USD","SG9999002406.SGD","SKYE","BK6516","LU0577902454.USD","LU0865486749.SGD","LU1508157978.USD","LU2506951958.HKD","LU0738912210.USD","LU0572939691.SGD","LU2663582299.SGD","SG9999016042.SGD","LU0577902371.SGD","LU0955669360.SGD","LU0048597586.USD","LU2238330802.EUR","LU0831103253.SGD","LU0516423174.USD","LU0048573645.USD","SG9999013486.USD","SG9999000343.SGD","LU0516422440.USD","LU0979878070.USD","LU2506952170.USD","LU1130305938.SGD","LU0588545490.SGD","BK6112","LU0572940350.SGD","LU0918141887.USD","SG9999013478.USD","LU0823417737.USD","LU2152927971.USD","LU0516423091.SGD","LU0348816934.USD","SG9999002679.SGD","LU0873338254.USD","SG9999002604.SGD","SG9999001135.SGD","LU1242518931.SGD","LU0823417653.USD","LU0516422366.SGD","LU2264538146.SGD","SG9999014484.SGD","LU0251144936.SGD","SG9999002414.USD","LU0261945553.USD","LU2506951875.HKD","BK6523","LU0251143029.SGD","SG9999014302.SGD","LU0348814723.USD","SG9999013460.SGD","LU0532188223.SGD","SG9999000475.SGD","SG9999002620.SGD","LU0588545904.SGD","SG9999004360.SGD","LU0878005551.USD","LU0516422952.EUR","LU1839390173.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636701846","title":"Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data From First Four Participants Treated in Cohort 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2636701846","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636701846?lang=en_us&edition=fundamental","pubTime":"2026-05-20 19:00","pubTimestamp":1779274801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nTUA77CP2D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SKYE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636084938","title":"Skye Bioscience Inc - Crc Approves Enrollment in Cohort 2 (600 Mg Iv) After Favorable Safety Review of Cohort 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2636084938","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636084938?lang=en_us&edition=fundamental","pubTime":"2026-05-20 19:00","pubTimestamp":1779274801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nTUA77CP2D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SKYE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636496948","title":"Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2636496948","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636496948?lang=en_us&edition=fundamental","pubTime":"2026-05-20 19:00","pubTimestamp":1779274800,"startTime":"0","endTime":"0","summary":"No Serious Adverse Events or Adverse Events of Special Interest Were Reported Following 4 Weeks of TreatmentSAN DIEGO, May  20, 2026  (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE), a clinic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/20/3298335/0/en/Skye-Announces-Cohort-Review-Committee-Approved-Opening-of-Cohort-2-Based-on-Favorable-Safety-Data-from-First-Four-Participants-Treated-in-Cohort-1.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","CRC","LU0456854461.SGD","LU0266512127.USD","BK4213","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635037365","title":"Skye Bioscience receives Nasdaq notice for falling below $10 million equity minimum","url":"https://stock-news.laohu8.com/highlight/detail?id=2635037365","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635037365?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:01","pubTimestamp":1778875289,"startTime":"0","endTime":"0","summary":"Skye Bioscience received Nasdaq notice of noncompliance with Global Market Listing Rule 5450 after reporting stockholders’ equity of 9.01 million in its quarterly filing for period ended March 31, 2026, below 10 million minimum.Nasdaq gave 45 days, until June 29, 2026, to submit plan to regain compliance; acceptance could allow extension to Nov. 9, 2026, to demonstrate equity at or above 10 million.Notice does not immediately affect listing or trading; shares continue to trade on Nasdaq Global Market under symbol SKYE.Failure to win plan approval could trigger delisting process, though appeal rights would keep shares listed during appeal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL8ZzH61:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635935241","title":"Skye Bioscience posts corporate presentation on nimacimab obesity drug development strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2635935241","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635935241?lang=en_us&edition=fundamental","pubTime":"2026-05-13 01:53","pubTimestamp":1778608398,"startTime":"0","endTime":"0","summary":"Skye Bioscience investor deck highlighted clinical combination data for obesity program pairing peripheral CB1 antibody nimacimab with semaglutide.CBeyond readout showed 3% incremental weight loss versus semaglutide alone at 26 weeks.Mean weight loss reached 22.3% at 52 weeks, with no plateau observed.Safety summary cited no nimacimab-associated neuropsychiatric signal through 52 weeks, with no additive gastrointestinal burden versus semaglutide.Development update flagged 200 mg weekly nimacimab monotherapy as underexposed in peripheral tissues, with a higher-dose expansion study under way to increase exposure.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL6xYhHl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635624906","title":"Update – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635624906","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635624906?lang=en_us&edition=fundamental","pubTime":"2026-05-13 01:33","pubTimestamp":1778607233,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA7ZZ0MM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SKYE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634298415","title":"U.S. RESEARCH ROUNDUP-Accuray, Aevex, Zoetis","url":"https://stock-news.laohu8.com/highlight/detail?id=2634298415","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634298415?lang=en_us&edition=fundamental","pubTime":"2026-05-12 15:21","pubTimestamp":1778570494,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Accuray, Aevex, ZoetisMay 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Accuray, Aevex and Zo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL4N41P0LT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CE","HIMZ","LU2089985449.USD","HIYY","FTV","ARAY","GTM","BK4106","BILL","APO","WPC","SIBN","ARES","MOS","SGI","BK4216","LU0476273544.USD","TOST","SNDA","VCTR","PLNT","CYTK","ALMR","LQDA","CVS","BX","AMAT","ELVN","BAM","LU2458330169.SGD","HIMS","SKYE","HIMY","SPG","LU0106831901.USD","ZTS","TRGP","LU0345781412.USD","VSNT","ASTH","TXG","KKR","TGT","CGNX","AGM","HMYY","AVEX","PSIX","LENZ","CEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634267214","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Coherus Biosciences (CHRS), Moderna (MRNA) and Skye Bioscience (SKYE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634267214","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634267214?lang=en_us&edition=fundamental","pubTime":"2026-05-12 14:40","pubTimestamp":1778568012,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Coherus Biosciences (CHRS), Moderna (MRNA) and Skye Bioscience (S...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-coherus-biosciences-chrs-moderna-mrna-and-skye-bioscience-skye-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-coherus-biosciences-chrs-moderna-mrna-and-skye-bioscience-skye-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNX","BK4534","BK4532","BK4533","XBI","BK4581","BK4588","CHRS","HCSG","BK4501","MRNA","BK4585","BK4535","BK4551","LU0128526141.USD","LU0029874061.USD","BK4139","BK4548","MRNY","LABU","XLV","BK4568","SKYE","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634250631","title":"Skye Bioscience Inc : Piper Sandler Cuts Target Price to $6 From $13","url":"https://stock-news.laohu8.com/highlight/detail?id=2634250631","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634250631?lang=en_us&edition=fundamental","pubTime":"2026-05-12 10:43","pubTimestamp":1778553802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nFWN41O1HS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SKYE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634232472","title":"Skye Bioscience Q1 EPS $(0.32) Misses $(0.31) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2634232472","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634232472?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:05","pubTimestamp":1778529911,"startTime":"0","endTime":"0","summary":"Skye Bioscience (NASDAQ:SKYE) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.31) by 3.23 percent. This is a 14.29 percent decrease over losses of $(0.28) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52467729/skye-bioscience-q1-eps-0-32-misses-0-31-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Skye Bioscience Q1 EPS $(0.32) Misses $(0.31) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634232511","title":"Skye Bioscience Q1 FY26 net loss widens to $12.51 million; operating loss rises to $12.67 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634232511","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634232511?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:02","pubTimestamp":1778529752,"startTime":"0","endTime":"0","summary":"Skye Bioscience posted a net loss of $12.51 million, widening from $11.1 million in prior-year quarter.Operating loss deepened to $12.67 million from $11.76 million, while no revenue was reported.Research and development expense rose 10% to $7.94 million, general and administrative expense increased 4% to $4.74 million.Cash, cash equivalents, and short-term investments fell to $17.11 million as of March 31, 2026, from $25.74 million at Dec. 31, 2025, with management expecting sufficient capital to operate through fourth-quarter 2026 excluding proposed Phase 2b and related manufacturing costs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via EDGAR, th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL496TzJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632372379","title":"Skye Bioscience Inc  expected to post a loss of 31 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2632372379","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632372379?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:10","pubTimestamp":1777893007,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc  expected to post a loss of31cents a share - Earnings Preview Skye Bioscience Inc SKYE.OQ SKYE.O is expected to  show no change in quarterly revenue when it reports  results on May","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL8N41H0VY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SKYE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":60,"code":"91000000","status":"200"}]}}